Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...
The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
(RTTNews) - Incyte Corp. (INCY) said that the U.S. Food and Drug Administration has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor or FGFR inhibitor, for the treatment ...
Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma The following represents disclosure information provided by the authors of ...
It has been previously demonstrated that the Bruton tyrosine kinase (BTK) pathway plays a key role promoting cell adhesion and chemotaxis, and that increased adhesion and aberrant chemotaxis ...
Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...
The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results